Actavis: Poised for the Future

Doug Boothe, Vice President

and Chief Operating Officer

or Actavis US

Generic pharmaceuticals are increasingly becoming a welcome refuge for patients, because they offer that rare combination of

controlling costs without sacrificing quality. Actavis is working to meet the growing demand for generics worldwide.

In 1999, Actavis was in a single country, its home of Iceland, with fewer than 150 employees. In a matter of just a decade, with aggressive product development and the acquisition and successful integration of 25 companies across the globe, Actavis is now among the top 5 leading developers of generic pharmaceuticals in the world. All in all, the company has approximately 850 products on the market globally, with nearly 350 more in active development.

Actavis has one of the broadest product portfolios and strongest pipelines in the business, with products that cover the full gamut of dosage forms, including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids, and semisolids. Diverse? Yes. Yet there is one common element to them all: helping make pharmaceuticals more affordable for consumers.

A Goal Accomplished Through a Winning Strategy

Growth of more than 2600% in 10 years does not come easily. From its beginnings, Actavis has been well managed and aggressive. Actavis focuses on its customers and on providing high-quality, lower-cost products — with a strong pipeline of new products and a team that is committed to bringing those products to market.

The company of 10,500 works tirelessly to bring a wide range of first-class generics to market and it keeps costs under control through continuous process improvement, resource optimization, and ongoing, careful analysis. It is a formula that has helped propel Actavis to a leading position in markets across the world.

Ready for Even More

After this intense period of growth, the company now has a solid foundation on which to build. It is investing strongly in and growing its research and development capability, with a focus on controlled-release products. It is expanding its dosage forms and is enhancing its quality systems

and production processes in its plants. Finally, it anticipates launching numerous abbreviated new drug applications this year, with many more to come.

For Actavis, it has been a fascinating, fast-paced journey from a small Icelandic company to an international organization, but it is one that was founded on the right idea: offering high-quality, affordable alternatives to brand name drugs.

A Quick Look at Actavis

• A leading developer and manufacturer of first-class generics.

• More than 10,500 employees in 40 countries (including 1400 in the United States).

• About 850 products on the market and 350 more on the way.

• Twenty-four billion tablet and caplet capacity.

• The name Actavis comes from two Latin words: acta, meaning action, and vis, meaning strength.

For more information, visit www.actavis.us.com.